



# FY25 Results Presentation

28 August 2025



# Disclaimer



The information contained in this document ("Document") has been prepared by Alcidion Group Limited ACN 143 142 410 (referred to as "Alcidion" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Alcidion periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at [www.asx.com.au](http://www.asx.com.au).

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein. The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast.

The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect

any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Alcidion's business and markets. Such information is generally based on independent market and industry data or research. The Alcidion has not independently verified, and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

## Financial data

All financial amounts contained in this presentation are expressed in Australian dollars (unless otherwise stated). Any discrepancies between totals and sums of components in tables, figures and body content contained in this presentation are due to rounding. Tables, figures and body content contained in this presentation have not been amended by ALC to correct immaterial summation differences that may arise from this rounding convention.

Investors should also be aware that certain financial data included in this presentation including underlying NPAT and underlying EBIT/EBITDA and measures described as "pro-forma", are "non-IFRS financial information" under ASIC regulatory Guide 230 (disclosing non-IFRS financial information). The non-IFRS financial information financial measures do not have a standardised meaning prescribed by Australian International Reporting Standards (AIFRS) and, therefore, may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other measures determined in accordance with AIFRS. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS financial measures included in this presentation.

# 01.

## Snapshot

ALCIDION  
CORPORATE OVERVIEW





# Alcidion: best-in-class – strong momentum and increasing scale



**Healthcare software and informatics company revolutionising efficiency and quality of care**



Industry leading, Australian-made healthcare software – now scaling as a key supplier in global markets.



100+ clinical implementations in Australia and abroad. Lucrative, long-term contracts expected to expand in size and value as new features are deployed.

Built to address problems in healthcare today and into the future



Strong financial profile (FY25 revenue \$40.8M) underpinned by increasing recurring revenue from long-term contracted customers.

Strong balance sheet with \$17.7M cash (at June-25) to deliver on future growth strategy




Highly experienced team with specialist expertise translating clinical needs into technical solutions.



Compelling platform **technology** - Miya Precision - transforming data interoperability and software integration to streamline patient flow, unify patient records, support clinical decision-making, and scale remote patient monitoring.

# Strong Market Share



Global footprint across the UK, Australia & NZ.



100+ clinical system implementations.



A platform approach to modernising healthcare assets and transforming the clinician experience.

# What is Miya Precision?

Miya Precision is a data platform for healthcare. However, it is more than that - Miya Precision digitises the clinical workflow and provides the foundation for the application of AI capability in healthcare.



## Designed for AI

Miya Precision has been designed for AI, enabling 3rd party applications to run and deliver insights to clinicians

## Digital Clinical Workflow

Miya Precision enables clinicians to fully coordinate patient care, tasks, alerts and communication digitally



## Integrate and Liberate Data

Maximise the value of exiting Health IT investments



**MIYA  
PRECISION**



## Operate in Real-Time

Systemwide transparency is available in real-time, showing bed availability, blockages, and critical events



## Intuitive User Interfaces

World leading visualisation and user experience

# Smarter Solutions for Clinicians



## Powering Smarter Care











At the core of Alcidion's solutions is our FHIR-based interoperability platform for smarter decision support



## Miya Precision Platform


Data to FHIR  
Ontology Mapping  
CDS Engine

### Solutions

 <b>Patient Flow &amp; Command</b> Digitised clinical workflow & patient journey visualisation	 <b>Emergency</b> Emergency Department and Specialised Care	 <b>Modular EPR</b> Modular cloud-native EPR, PAS & AI enabled Noting	 <b>Virtual Care</b> Virtual care and remote patient management	 <b>Integrated Care Record</b> Longitudinal patient health record
 <b>Inpatient Solutions</b> EPR, PAS, Noting, Flow, Bed, Task and Results Mgmt	 <b>Outpatient Solutions</b> Appointment Mgmt, Clinical Mgmt, Documentation	 <b>Aged Care Flow</b> Integrated Care Record, Record Exchange, AI Enabled Intervention	 <b>Community &amp; Mental Health</b> Integrated Care Record, Clinical Assessments and Documentation	 <b>Military Health</b> Integrated Care Record, IPS, Garrison/Deployed , Offline Operations

### Settings

# The modular Miya Precision platform





# 02.

## FY25 Highlights

EXECUTIVE SUMMARY

# A Record Year for Alcidion

## Building blocks in place to accelerate global growth



- ① **Scale** - FY25 revenue of \$40.8M with geographical split 63% from UK & 37% from ANZ
- ② **Validation** - New TCV<sup>1</sup> of \$73.8M, up 109% pcp; led by milestone \$39m+ EPR<sup>2</sup> contract
- ③ **Profitability** - Record Underlying EBITDA<sup>3</sup> of \$5.1m; \$5.8M positive operating cashflow
- ④ **Stability** – ARR<sup>4</sup> (as at 30 June 2025) of \$28.5M, up 31% on pcp, underpins future profitability
- ⑤ **Momentum** – FY26 starting contracted revenue of \$34M<sup>5</sup>; increases with contract wins during the year
- ⑥ **Growth Drivers** – Healthcare platform focusing on Flow & EPR opportunities, module expansion, adjacent markets, geographical expansion
- ⑦ **Market Need** – Healthcare systems operating under increasing pressure to improve efficiency

1. Total Contract Value

2. Electronic Patient Record

3. Underlying EBITDA: EBITDA excluding share-based payments and one-off restructure costs

4. Annual Recurring Revenue defined as the value of Support & Maintenance (S&M), hosting and/or license revenue that is contracted to be billed annually. This does not include multi-year capital licenses paid during the year or which will reoccur again upon a future contract renewal. ARR is a measure of the future annualised revenue as at a point in time.

5. Basis for calculation: ARR (\$28.5M) + contracted implementation and technical services revenue (\$5.5M)

# FY25 – Financial Highlights

## A record year across all key financial metrics



**\$40.8M**

FY25 revenue

Up **10%** on pcp<sup>1</sup>

Several new contract wins  
incl. milestone \$39m+  
North Cumbria contract

**\$28.5M**

ARR<sup>1</sup> (as at 30 Jun-25)

Up **31%** on 30 Jun-24

Increasing recurring  
revenue base supported  
by contracted  
implementation and  
technical services

**\$73.8M**

FY25 new & renewal TCV

Up **109%** on pcp

**\$5.1M**

Underlying EBITDA<sup>3</sup>

Up **\$8.5M** vs. (\$3.4m)  
loss in FY24

EBITDA of **\$4.8M**

Fixed costs down **10%**  
pcp

**\$5.8M**

Operating Cashflow  
positive

Up **\$12.9M** vs. (\$7.1M)  
loss in FY24

**\$4.9m** net cashflow  
positive in FY25

**\$17.7M** cash

1. Comparisons are to prior corresponding period (FY24)

2. Annual Recurring Revenue defined as the value of Support & Maintenance (S&M), hosting and/or license revenue that is contracted to be billed annually. This does not include multi-year capital licenses paid during the year or which will reoccur again upon a future contract renewal. ARR is a measure of the future annualised revenue as at a point in time.

3. Underlying EBITDA: EBITDA excluding share-based payments and one-off restructure costs

# FY25 – Operational Highlights



## A record year for new TCV wins; long-term contracts position for future success

### New & Renewal Contracts

- › New contracts:
  - › Jul-24: Hume Rural Health Alliance (AUS): Miya Precision as an enterprise digital platform; focus on patient flow
  - › Nov-24: North Adelaide Local Health Network (AUS): Miya Precision & mobile clinical comms and tasking
  - › Nov-24: Peninsula Health (AUS): Miya Precision deployment and mobile tasking
  - › Feb-25: Hywel Dda (Wales): Contract for Miya Flow, Obs and Assessments and mobile comms
  - › Feb-25: North Cumbria NHS Trust<sup>2</sup> (UK): Contract for new EPR solution and extended to mobile comms
- › Expanded (value) and extended (term) several existing contracts further validating long-term nature of customer relationships

### Leadership

- › Continued to evolve Alcidion Board to ensure relevant expertise and experience to deliver next phase of growth:
  - › Appointed William Smart (NED, UK) – currently Digital NED, Great Western NHS, previously Senior Exec at Dedalus Group
  - › Appointed Professor Andrew Way AM (NED, Aus) – previously served as CEO of Alfred Health for 15 years (ending in 2024)
- › Post FY25 period end – strengthened leadership team with three key appointments:
  - › Paul Deffley as Managing Director UK - also retains current role as Chief Medical Officer
  - › Darren Ransley as Chief Revenue Officer - Previously MD UK for Better & SVP Global Sales for CliniSys
  - › Tracey McLelland as Chief Clinical Information Officer – previously CCIO UK for Dedalus



# 03.

## Financial Results

FY25 RESULTS





# Profit & Loss



## Record Revenue and Underlying EBITDA; underpinned by growth in ARR


Profit & loss (A\$000)		FY24	FY25	% Change
<b>Recurring</b>				
Product - M&S + Annual licences	1	26,197	25,968	(1%)
Product - Capital licences	2	1,081	8,440	681%
<b>Non-Recurring</b>				
Product Implementation	3	7,496	4,753	(37%)
Technical services		2,283	1,625	(29%)
<b>Total revenue</b>		<b>37,057</b>	<b>40,786</b>	<b>10%</b>
Direct costs		(5,137)	(4,797)	(7%)
<b>Gross profit</b>		<b>31,920</b>	<b>35,989</b>	<b>13%</b>
Gross profit %		86.1%	88.2%	
Salaries & wages	4	(29,236)	(26,212)	(10%)
Professional fees		(941)	(1,093)	16%
Marketing		(928)	(743)	(20%)
Other operating expenses		(4,209)	(3,780)	(10%)
Foreign exchange gain		34	935	na
<b>Operating expenses</b>	4	<b>(35,280)</b>	<b>(30,893)</b>	<b>(12%)</b>
<b>Underlying EBITDA</b>	5	<b>(3,360)</b>	<b>5,096</b>	<b>na</b>
Restructure & related costs		(1,033)	(118)	na
Share based payments		(152)	(134)	(12%)
<b>EBITDA</b>		<b>(4,545)</b>	<b>4,843</b>	<b>na</b>

- 1 › Annual recurring product revenue (M&S + Annual Licences) in FY25 reflects only partial contribution from new customers won during FY25
  - › ARR as of 30 June 2025 of ~\$28.5M, up 31% pcp
- 2 › Material uplift in capital license revenue reflects upfront payment of 10-year North Cumbria license fee (typically a feature of larger UK contracts)
  - › Capital license due again upon contract renewal representing material future earnings upside (for all capital license contracts)
- 3 › Lower implementation revenue due to completion of Alcidion's portion of implementation for the Leidos-led Aust DoD healthtech project in FY24
  - › Technical Services reflects rolling annual services contracts
- 4 › Disciplined cost management maintained during FY25; staff costs and total operating costs (excl. gain on FX) down 10% on pcp
- 5 › Record Underlying EBITDA of \$5.1m


# Revenue Dashboard




H1 vs H2  
Revenue  
Split (\$M)




Geographical  
Split (%)



Revenue  
Category  
Breakdown  
(\$M)




% Recurring  
(product) of  
Total Revenue



# Our revenue model & breakdown...



Licence fees + Maintenance & Support (M&S) recurring revenue will underpin future sustainable and increasingly profitable growth



1. Approximate percentage of FY25 revenue; Technical Services revenue will continue to decrease as % total revenue into the future

# Balance Sheet



## Significant balance sheet flexibility to pursue growth opportunities

Balance sheet (\$000)		FY24	FY25
Cash & cash equivalents	1	11,798	17,697
Trade & other receivables		5,214	3,680
Other assets		1,527	2,310
<b>Current assets</b>		<b>18,539</b>	<b>23,688</b>
Plant & equipment		384	250
Intangible assets	2	93,951	90,350
ROU assets		1,586	1,337
<b>Total assets</b>		<b>114,460</b>	<b>115,625</b>
Trade & other payables		3,233	2,274
Employee provisions		2,316	2,927
Unearned revenue	3	12,826	15,038
Income tax payable		134	(89)
Lease liabilities		697	711
<b>Total current liabilities</b>		<b>19,206</b>	<b>20,862</b>
Employee Provisions		148	182
Other Provisions		443	470
Lease liabilities		998	694
Deferred tax liabilities		6,725	5,617
<b>Total liabilities</b>		<b>27,520</b>	<b>27,824</b>
<b>Net assets</b>		<b>86,940</b>	<b>87,801</b>

- 1 › \$17.7m cash and no debt as of 30 June 2025
- 2 › Relates primarily to the acquired intangibles from the ExtraMed and Silverlink acquisitions
- 3 › Increased unearned revenue of \$15.0M reflects the stronger revenues generated in FY25
  - › Unearned revenue is invoiced in advance of products / services being delivered (typically M&S or subscription revenue)
  - › Revenue is recognised in accordance with AASB 15 (revenue from contracts with customers)

# Cashflow

Cash flow (\$000)		FY24	FY25
Receipts from customers	1	43,881	50,858
Payments to suppliers & employees		(50,831)	(45,162)
Interest received		83	148
Finance costs		(89)	(81)
Income Tax Paid		(173)	-
<b>Cash (outflow) from operating activities</b>	2	<b>(7,129)</b>	<b>5,763</b>
Payment for PP&E		(53)	(125)
Acquisition of business, net of cash acquired		-	-
<b>Net Cash (used) for investing activities</b>	3	<b>(53)</b>	<b>(125)</b>
Net proceeds for issues of equity securities		5,403	-
Transaction costs related to issues of equity securities		(399)	-
Payment for principal portion of lease liabilities		(662)	(764)
<b>Net Cash (outflows)/inflows from financing activities</b>		<b>4,342</b>	<b>(764)</b>
Cash & cash equivalents opening balance		14,641	11,798
Net (decrease)/increase in cash & cash equivalents	4	(2,840)	4,874
Effects of exchange rate changes		(3)	1,025
<b>Cash &amp; cash equivalents closing balance</b>		<b>11,798</b>	<b>17,697</b>

- 1 › Cash receipts materially exceeding revenue largely driven by inclusion of relevant jurisdiction tax (ie. 10% GST in Australian and 20% VAT in UK)
- 2 › Generated record positive operating cashflow of \$5.8M in FY25
- 3 › Alcidion does not capitalise any R&D spend
- 4 › Net positive cashflow for FY25 of \$4.9M



# 04.

## Operational Success

POSITIONED FOR GROWTH



# Notable New Contract Wins



**New contracts reinforce modular strategy, catering to needs of customers as they enhance their digital maturity**



## Hume Rural Health Alliance (AUS)

- › Miya Precision deployed as an enterprise digital platform across multiple sites in regional Victoria with a focus on patient flow and virtual care



## Hywel Dda (Wales)

- › Miya Precision – Patient Flow, Observations & Assessments and Smartpage
- › First customer in Wales



## North Adelaide Local Health Network (AUS)

- › Miya Precision deployed across portfolio of the South Australian Department for Health and Wellbeing
- › First SA Miya Precision deployment



## Peninsula Health (AUS)

- › Miya Precision deployed as an electronic patient flow management solution within all Peninsula Health sites.
- › Platform integrated with the existing EMR highlighting Alcidion's ability to integrate with existing solutions

# EPR Validation: North Cumbria



## Signed contract with North Cumbria Integrated Care NHS Foundation Trust (NCIC) for new EPR platform solution

### Key Contract Terms



10 years

Contract duration



A\$39.0M+

Total Contract Value (TCV)\*



Potential to add further modules over time

### Contract Signed - Overview

- › Selected following a competitive tender process
- › Deploy Miya Precision encompassing full suite offering incl. Silverlink PCS
- › NCIC is an existing Alcidion customer utilising Silverlink PCS PAS
- › Solution will provide clinicians real-time access to patient records while streamlining patient flow & improving clinical decision-making processes

### Traction in UK EPR Market

- › 2nd UK EPR contract following 10 year \$23m extension of South Tees contract signed in Dec-23.
  - › South Tees has optionality for additional modules; if selected would add TCV of \$10m+ and thus similar size to NCIC
- › NCIC and South Tees provide two good reference points as to the shape and size of various EPR contracts



### NCIC - Overview

- › Provides care for approx. half a million people in the North of the UK
- › Hospital & community care provided across:
  - › 2 acute care hospitals
  - › 8 community-based hospitals
  - › 8 Integrated Care Communities (ICC)

# Notable Extension / Expansion Wins

Continuing to build on deeply embedded and long-standing relationships



## NT Health (AUS)

- › Builds upon existing 9+ year relationship
- › Miya Precision to include reseller arrangement with 3<sup>rd</sup> party vendor's comms team messaging capability – highlights interoperability of Miya platform to suite needs of customers
- › Scale of Miya platform presents opportunities for incremental value via reseller partnerships

## PCS Customers

### Several PCS customers (UK)

- › Extended several PCS customers (product name for Silverlink) for between 1-3 years
- › Continues to validate long-term nature of customer relationships and the critical role PAS software plays in hospital operations



## Sydney LHD (AUS)

- › Extends 5-year relationship for a further 2 years
- › Miya Precision used to support ongoing virtual and remote patient monitoring offering via Sydney LHD's virtual hospital (rpavirtual)
- › rpavirtual was one of Australia's first virtual hospitals and played a critical role during the COVID-pandemic



## Hume Rural Health Alliance (AUS)

- › Recently expanded to include further modules in the original sites
- › Potential for module expansion in future periods

# Successful Deployments in FY25

## Product Implementation and technical service delivery have always been a strength of the Alcidion business



### Hume Rural Health Alliance (AUS)

- › First site went 'live' in late Oct-24
- › Additional sites followed in in Nov / Dec
- › Fastest ever roll-out of the Miya Precision platform, validating strength of Alcidion's technical services team



### Hampshire Hospitals NHS Foundation Trust

- › First deployment of Miya Emergency across three hospitals of the trust
- › Clinical professionals and end users were deeply involved during the implementation

“...staff see enormous potential in Miya Emergency to help them... The system works extremely well, providing cross-trust visibility of what is going on in our emergency departments.

Dr Tamara Everington, CCIO



### Dartford and Gravesham NHS Trust

- › Successful roll out of electronic prescribing and medicine management (EPMA) system
- › Fully integrated & accessible from Miya Precision

“EPMA allows us to implement strong barriers to error for high-risk medication, whereas in the past we were reliant on weak barriers such as training and guidelines.

Julia Scott, Pharmacist



### Royal Bolton Hospital

- › Longstanding Patienttrack customer
- › Deployment of Miya Flow to deliver systemwide transparency
- › Bed management processes digitised and administrative burden on staff reduced

“This deployment represents a fundamental part of our plans to embed a control centre within the trust. This will only help to enhance both patient experience and patient safety.

Dawn Devine, Head of Clinical Systems




# Modular / Expansion sales driving TCV uplift



Delivering tangible examples of strategies success...

<b>Hume (Aust.)</b> <ul style="list-style-type: none"><li>• Q1'25 – New contract covering 15 hospitals across Hume region of Vic, Australia</li><li>• Q4'25 – expanded to include additional hospital sites</li></ul>	<b>North Cumbria (UK)</b> <ul style="list-style-type: none"><li>• Q3'25 – Milestone 10-year contract for EPR solution (several Miya modules)</li><li>• Q4'25 – expanded to include clinical comms module</li></ul>	<b>South Tees (UK)</b> <ul style="list-style-type: none"><li>• Q2'20 - 5 years for several Miya modules</li><li>• Q2'20 - module expansion</li><li>• Q2'23 – extended contract for 8 yrs with options on new modules</li></ul>	<b>NT Health</b> <ul style="list-style-type: none"><li>• Extended to include Smartpage task management alongside including partner module for communication from Celo</li></ul>
---	--	--	---

Illustrative example of progressive module sales; unique ability to accommodate customers budget and requirements



# 06.

## Outlook

STRONG OUTLOOK  
AND GROWTH POTENTIAL

# Outlook



## Momentum continuing into FY26 underpinned by high contracted revenue coupled with maturing pipeline of expansion & new opportunities



As of 30 June 2025, contracted & renewal revenue to be recognised in FY26 of \$34.0M;

Contracted revenue will increase during the year as new sales are won



Targeting to be FY26 EBITDA positive and deliver positive operating cashflow

Quantum depends on timing of new contract wins



Started market testing, partner discussions, customer analysis for entry into new geographies – specifically Canada, Saudi Arabia & UAE  
Progress to accelerate during FY26



Reviewing Miya platform applicability for other health verticals to complement existing capability (key targets verticals include aged care & community care)



Continuing building on referenceability in our core products to further penetrate our key markets; important role in the selection criteria



Reviewing potential M&A opportunities to accelerate growth profile

# Investment Highlights



## Large Addressable Market

- › Strong foothold within approximately 1/3<sup>rd</sup> of UK NHS acute Trusts using at least one ALC module
- › Focus on management of patient flow creating increasing opportunities in ANZ
- › AUS opportunity in virtual care setting and remote patient monitoring – aged care
- › Geographical expansion on radar

## Strong Financial Profile

- › \$40.8M FY25 revenue
- › \$28.5m ARR (as of 30 Jun-25) underpinned by multi-year (typically 3-5 year) contracts
- › Gross profit margins 88%+
- › Scale and operating leverage emerging - FY25 Underlying EBITDA of \$5.1M & operating cashflow of \$5.8M

## Strong Marquee Customers

- › \$39.0M+ over 10 years with North Cumbria for Miya Precision suite to provide new EPR
- › \$31.7M over 5.5 years with Leidos (Aus) to assist Australian Defence Force with health record
- › \$23.0M over 10 years (to 2033) with South Tees NHS (UK) for full Miya Precision suite

## Product Offering

- › Cloud native, modern modular platform improving hospital efficiencies and clinical decision-making
- › Highly interoperable and built on open standards
- › Designed to be an active participant in health care rather than passive data store

## Long-term Contracts

- › Long-term customer contracts (typically 3-5 years) with ongoing options for renewal
- › Critical nature of software results in negligible churn
- › Enterprise healthcare organisations (NHS Trusts, State health, private health)

## Market Tailwinds

- › Health systems stretched with limited bed availability & under-resourced clinical staff seeking improved tech solutions for efficiency
- › UK Government remaining committed to their pursuit of modernising the NHS, significant funding being allocated

